To examine the anti-proliferative mechanisms of Src inhibition, two sensitive (HCT116 and LS174T) and two resistant (HT15 and SW620) CRC cell lines were treated with dasatinib (0.08 μmol/L) and the proportion of cells cycling in G1, S and G2M were determined after 24 hours of treatment. This evidence concerns the gene SRC and colorectal carcinoma.